Short- and long-term exposure of articular cartilage to curcumin or quercetin inhibits aggrecan loss

Journal of Nutritional Biochemistry

Volumn 23, Issue 2, 2012, Pages 106-112

  Lay, Eileen ^a   Samiric, Tom ^a   Handley, Christopher J ^a   Ilic, Mirna Z ^a  

^a LA TROBE UNIVERSITY   (Australia)

Author keywords

ADAMTS 4; ADAMTS 5; Aggrecan; Cartilage; Curcumin; Quercetin

Indexed keywords

AGGRECAN; AGGRECANASE 1; AGGRECANASE 2; CURCUMIN; INTERLEUKIN 1ALPHA; METALLOPROTEINASE; QUERCETIN; RETINOIC ACID; THROMBOSPONDIN;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; ARTICULAR CARTILAGE; CONTROLLED STUDY; COW; DOSE RESPONSE; DRUG EFFECT; EXPLANT; NONHUMAN; PROTEIN DEGRADATION; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN MOTIF; PROTEIN SYNTHESIS;

ADAM PROTEINS; AGGRECANS; ANIMALS; CARTILAGE, ARTICULAR; CATTLE; CURCUMIN; ENDOPEPTIDASES; GENE EXPRESSION REGULATION; INTERLEUKIN-1ALPHA; ORGAN CULTURE TECHNIQUES; PROCOLLAGEN N-ENDOPEPTIDASE; QUERCETIN; TRETINOIN;

BOVINAE;

EID: 84855512373     PISSN: 09552863     EISSN: 18734847     Source Type: Journal    
DOI: 10.1016/j.jnutbio.2010.11.004     Document Type: Article

References (61)

1. Martel-Pelletier J., Boileau C., Pelletier J.P., Roughley P.J. Cartilage in normal and osteoarthritis conditions. Best Pract Res Clin Rheumatol 2008, 22:351-384.
2. Sandell L.J. Modern molecular analysis of a traditional disease: progression in osteoarthritis. Arthritis Rheum 2007, 56:2474-2477.
3. Abbaszade I., Liu R.Q., Yang F., Rosenfeld S.A., Ross O.H., Link J.R., et al. Cloning and characterization of ADAMTS11, an aggrecanase from the ADAMTS family. J Biol Chem 1999, 274:23443-23450.
4. Tortorella M.D., Burn T.C., Pratta M.A., Abbaszade I., Hollis J.M., Liu R., et al. Purification and cloning of aggrecanase-1: a member of the ADAMTS family of proteins. Science 1999, 284:1664-1666.
5. Sondergaard B.C., Schultz N., Madsen S.H., Bay-Jensen A.C., Kassem M., Karsdal M.A. MAPKs are essential upstream signaling pathways in proteolytic cartilage degradation - divergence in pathways leading to aggrecanase and MMP-mediated articular cartilage degradation. Osteoarthritis Cartilage 2009.
6. Ghosh P. The pathobiology of osteoarthritis and the rationale for the use of pentosan polysulfate for its treatment. Semin Arthritis Rheum 1999, 28:211-267.
7. Reginster J.Y., Deroisy R., Rovati L.C., Lee R.L., Lejeune E., Bruyere O., et al. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet 2001, 357:251-256.
8. Zhang W., Moskowitz R.W., Nuki G., Abramson S., Altman R.D., Arden N., et al. OARSI recommendations for the management of hip and knee osteoarthritis, part I: critical appraisal of existing treatment guidelines and systematic review of current research evidence. Osteoarthritis Cartilage 2007, 15:981-1000.
9. Henrotin Y., Clutterbuck A.L., Allaway D., Lodwig E.M., Harris P., Mathy-Hartert M., et al. Biological actions of curcumin on articular chondrocytes. Osteoarthritis Cartilage 2009.
10. Jackson J.K., Higo T., Hunter W.L., Burt H.M. The antioxidants curcumin and quercetin inhibit inflammatory processes associated with arthritis. Inflamm Res 2006, 55:168-175.
11. Lim H., Kim H.P. Inhibition of mammalian collagenase, matrix metalloproteinase-1, by naturally-occurring flavonoids. Planta Med 2007, 73:1267-1274.
12. Liacini A., Sylvester J., Li W.Q., Huang W., Dehnade F., Ahmad M., et al. Induction of matrix metalloproteinase-13 gene expression by TNF-alpha is mediated by MAP kinases, AP-1, and NF-kappaB transcription factors in articular chondrocytes. Exp Cell Res 2003, 288:208-217.
13. Liacini A., Sylvester J., Li W.Q., Zafarullah M. Inhibition of interleukin-1-stimulated MAP kinases, activating protein-1 (AP-1) and nuclear factor kappa B (NF-kappa B) transcription factors down-regulates matrix metalloproteinase gene expression in articular chondrocytes. Matrix Biol 2002, 21:251-262.
14. Pattoli M.A., MacMaster J.F., Gregor K.R., Burke J.R. Collagen and aggrecan degradation is blocked in interleukin-1-treated cartilage explants by an inhibitor of IkappaB kinase through suppression of metalloproteinase expression. J Pharmacol Exp Ther 2005, 315:382-388.
15. Sylvester J., Liacini A., Li W.Q., Zafarullah M. Interleukin-17 signal transduction pathways implicated in inducing matrix metalloproteinase-3, -13 and aggrecanase-1 genes in articular chondrocytes. Cell Signal 2004, 16:469-476.
16. Handley C.J., Campbell M.A. Catabolism and turnover of proteoglycans. Methods Enzymol 1987, 144:412-419.
17. Oegema T.R., Hascall V.C., Eisenstein R. Characterization of bovine aorta proteoglycan extracted with guanidine hydrochloride in the presence of protease inhibitors. J Biol Chem 1979, 254:1312-1318.
18. Samiric T., Parkinson J., Ilic M.Z., Cook J., Feller J.A., Handley C.J. Changes in the composition of the extracellular matrix in patellar tendinopathy. Matrix Biol 2009, 28:230-236.
19. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25:402-408.
20. Ilic M.Z., Martinac B., Handley C.J. Effects of long-term exposure to glucosamine and mannosamine on aggrecan degradation in articular cartilage. Osteoarthritis Cartilage 2003, 11:613-622.
21. Campbell M.A., Handley C.J. The effect of retinoic acid on proteoglycan biosynthesis in bovine articular cartilage cultures. Arch Biochem Biophys 1987, 253:462-474.
22. Mathy-Hartert M., Jacquemond-Collet I., Priem F., Sanchez C., Lambert C., Henrotin Y. Curcumin inhibits pro-inflammatory mediators and metalloproteinase-3 production by chondrocytes. Inflamm Res 2009, 58:899-908.
23. Toegel S., Wu S.Q., Piana C., Unger F.M., Wirth M., Goldring M.B., et al. Comparison between chondroprotective effects of glucosamine, curcumin, and diacerein in IL-1beta-stimulated C-28/I2 chondrocytes. Osteoarthritis Cartilage 2008, 16:1205-1212.
24. Shakibaei M., John T., Schulze-Tanzil G., Lehmann I., Mobasheri A. Suppression of NF-kappaB activation by curcumin leads to inhibition of expression of cyclo-oxygenase-2 and matrix metalloproteinase-9 in human articular chondrocytes: implications for the treatment of osteoarthritis. Biochem Pharmacol 2007, 73:1434-1445.
25. Panico A.M., Cardile V., Santagati N.A., Messina R. Antioxidant and protective effects of sumac leaves on chondrocytes. J Med Plant Res 2009, 3:855-861.
26. Vergoten G., Zanetta J.P. Structural differences between the putative carbohydrate-recognition domains of human IL-1 alpha, IL-1 beta and IL-1 receptor antagonist obtained by in silico modeling. Glycoconj J 2007, 24:183-193.
27. Sztrolovics R., Recklies A.D., Roughley P.J., Mort J.S. Hyaluronate degradation as an alternative mechanism for proteoglycan release from cartilage during interleukin-1beta-stimulated catabolism. Biochem J 2002, 362:473-479.
28. Clutterbuck A.L., Mobasheri A., Shakibaei M., Allaway D., Harris P. Interleukin-1beta-induced extracellular matrix degradation and glycosaminoglycan release is inhibited by curcumin in an explant model of cartilage inflammation. Ann N Y Acad Sci 2009, 1171:428-435.
29. Ilic M.Z., Robinson H.C., Handley C.J. Characterization of aggrecan retained and lost from the extracellular matrix of articular cartilage. Involvement of carboxyl-terminal processing in the catabolism of aggrecan. J Biol Chem 1998, 273:17451-17458.
30. Munteanu S.E., Ilic M.Z., Handley C.J. Calcium pentosan polysulfate inhibits the catabolism of aggrecan in articular cartilage explant cultures. Arthritis Rheum 2000, 43:2211-2218.
31. Malfait A.M., Liu R.Q., Ijiri K., Komiya S., Tortorella M.D. Inhibition of ADAM-TS4 and ADAM-TS5 prevents aggrecan degradation in osteoarthritic cartilage. J Biol Chem 2002, 277:22201-22208.
32. Patwari P., Gao G., Lee J.H., Grodzinsky A.J., Sandy J.D. Analysis of ADAMTS4 and MT4-MMP indicates that both are involved in aggrecanolysis in interleukin-1-treated bovine cartilage. Osteoarthritis Cartilage 2005, 13:269-277.
33. Song R.H., Tortorella M.D., Malfait A.M., Alston J.T., Yang Z., Arner E.C., et al. Aggrecan degradation in human articular cartilage explants is mediated by both ADAMTS-4 and ADAMTS-5. Arthritis Rheum 2007, 56:575-585.
34. Tortorella M.D., Malfait A.M., Deccico C., Arner E. The role of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) in a model of cartilage degradation. Osteoarthritis Cartilage 2001, 9:539-552.
35. Glasson S.S., Askew R., Sheppard B., Carito B., Blanchet T., Ma H.L., et al. Deletion of active ADAMTS5 prevents cartilage degradation in a murine model of osteoarthritis. Nature 2005, 434:644-648.
36. Ilic M.Z., East C.J., Rogerson F.M., Fosang A.J., Handley C.J. Distinguishing aggrecan loss from aggrecan proteolysis in ADAMTS-4 and ADAMTS-5 single and double deficient mice. J Biol Chem 2007, 282:37420-37428.
37. Stanton H., Rogerson F.M., East C.J., Golub S.B., Lawlor K.E., Meeker C.T., et al. ADAMTS5 is the major aggrecanase in mouse cartilage in vivo and in vitro. Nature 2005, 434:648-652.
38. Pratta M.A., Scherle P.A., Yang G., Liu R.Q., Newton R.C. Induction of aggrecanase 1 (ADAM-TS4) by interleukin-1 occurs through activation of constitutively produced protein. Arthritis Rheum 2003, 48:119-133.
39. Fosang A.J., Rogerson F.M. Identifying the human aggrecanase. Osteoarthritis Cartilage 2010, 18:1109-1116.
40. Echtermeyer F., Bertrand J., Dreier R., Meinecke I., Neugebauer K., Fuerst M., et al. Syndecan-4 regulates ADAMTS-5 activation and cartilage breakdown in osteoarthritis. Nat Med 2009, 15:1072-1076.
41. Gao G., Plaas A., Thompson V.P., Jin S., Zuo F., Sandy J.D. ADAMTS4 (aggrecanase-1) activation on the cell surface involves C-terminal cleavage by glycosylphosphatidyl inositol-anchored membrane type 4-matrix metalloproteinase and binding of the activated proteinase to chondroitin sulfate and heparan sulfate on syndecan-1. J Biol Chem 2004, 279:10042-10051.
42. Hamalainen M., Nieminen R., Vuorela P., Heinonen M., Moilanen E. Anti-inflammatory effects of flavonoids: genistein, kaempferol, quercetin, and daidzein inhibit STAT-1 and NF-kappaB activations, whereas flavone, isorhamnetin, naringenin, and pelargonidin inhibit only NF-kappaB activation along with their inhibitory effect on iNOS expression and NO production in activated macrophages. Mediators Inflamm 2007, 2007:45673.
43. Berenbaum F. Signaling transduction: target in osteoarthritis. Curr Opin Rheumatol 2004, 16:616-622.
44. Tiku M.L., Yan Y.P., Chen K.Y. Hydroxyl radical formation in chondrocytes and cartilage as detected by electron paramagnetic resonance spectroscopy using spin trapping reagents. Free Radic Res 1998, 29:177-187.
45. Funk J.L., Frye J.B., Oyarzo J.N., Kuscuoglu N., Wilson J., McCaffrey G., et al. Efficacy and mechanism of action of turmeric supplements in the treatment of experimental arthritis. Arthritis Rheum 2006, 54:3452-3464.
46. Puangpraphant S., de Mejia E.G. Saponins in yerba mate tea ( Ilex paraguariensis A. St.-Hil) and quercetin synergistically inhibit iNOS and COX-2 in lipopolysaccharide-induced macrophages through NFkappaB pathways. J Agric Food Chem 2009, 57:8873-8883.
47. Tang D., Kang R., Xiao W., Zhang H., Lotze M.T., Wang H., et al. Quercetin prevents LPS-induced high-mobility group box 1 release and proinflammatory function. Am J Respir Cell Mol Biol 2009, 41:651-660.
48. Brew K., Nagase H. The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity. Biochim Biophys Acta 1803, 2010:55-71.
49. Cheng A.L., Hsu C.H., Lin J.K., Hsu M.M., Ho Y.F., Shen T.S., et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 2001, 21:2895-2900.
50. Dunnick J.K., Hailey J.R. Toxicity and carcinogenicity studies of quercetin, a natural component of foods. Fundam Appl Toxicol 1992, 19:423-431.
51. Davalos A., Castilla P., Gomez-Cordoves C., Bartolome B. Quercetin is bioavailable from a single ingestion of grape juice. Int J Food Sci Nutr 2006, 57:391-398.
52. Manach C., Williamson G., Morand C., Scalbert A., Remesy C. Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies. Am J Clin Nutr 2005, 81:230S-242S.
53. Boulton D.W., Walle U.K., Walle T. Extensive binding of the bioflavonoid quercetin to human plasma proteins. J Pharm Pharmacol 1998, 50:243-249.
54. Makino T., Shimizu R., Kanemaru M., Suzuki Y., Moriwaki M., Mizukami H. Enzymatically modified isoquercitrin, alpha-oligoglucosyl quercetin 3-O-glucoside, is absorbed more easily than other quercetin glycosides or aglycone after oral administration in rats. Biol Pharm Bull 2009, 32:2034-2040.
55. Mertens-Talcott S.U., Bomser J.A., Romero C., Talcott S.T., Percival S.S. Ellagic acid potentiates the effect of quercetin on p21waf1/cip1, p53, and MAP-kinases without affecting intracellular generation of reactive oxygen species in vitro. JNutr 2005, 135:609-614.
56. Wang Y.J., Pan M.H., Cheng A.L., Lin L.I., Ho Y.S., Hsieh C.Y., et al. Stability of curcumin in buffer solutions and characterization of its degradation products. J Pharm Biomed Anal 1997, 15:1867-1876.
57. Anand P., Kunnumakkara A.B., Newman R.A., Aggarwal B.B. Bioavailability of curcumin: problems and promises. Mol Pharm 2007, 4:807-818.
58. Graefe E.U., Wittig J., Mueller S., Riethling A.K., Uehleke B., Drewelow B., et al. Pharmacokinetics and bioavailability of quercetin glycosides in humans. J Clin Pharmacol 2001, 41:492-499.
59. Kroon P.A., Clifford M.N., Crozier A., Day A.J., Donovan J.L., Manach C., et al. How should we assess the effects of exposure to dietary polyphenols in vitro?. Am J Clin Nutr 2004, 80:15-21.
60. Tomren M.A., Masson M., Loftsson T., Tonnesen H.H. Studies on curcumin and curcuminoids XXXI. Symmetric and asymmetric curcuminoids: stability, activity and complexation with cyclodextrin. Int J Pharm 2007, 338:27-34.
61. Tonnesen H.H., Masson M., Loftsson T. Studies of curcumin and curcuminoids. XXVII. Cyclodextrin complexation: solubility, chemical and photochemical stability. Int J Pharm 2002, 244:127-135.